{
    "clinical_study": {
        "@rank": "31716", 
        "arm_group": [
            {
                "arm_group_label": "1", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "2", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "Cerebral Amyloid Angiopathy (CAA) is a condition caused by the build-up of a protein called\n      amyloid, predominantly A\u03b240, within the walls of brain blood vessels, especially those blood\n      vessels in the occipital lobe of the brain. Probable CAA may be defined as two or more\n      hemorrhages in the brain cortex in individuals 55 years of age or older.  This study will\n      examine the study drug (PF-04360365) vs. placebo (saline) at 10 mg/kg - Day 1 and the\n      maintenance dose of the study drug (PF-04360365) vs. placebo (saline) at 7.5mg/kg on Days 30\n      and 60. Subjects will be followed for 6 months after receiving the last dose of study\n      medication."
        }, 
        "brief_title": "Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Cerebral Amyloid Angiopathy", 
        "condition_browse": {
            "mesh_term": "Cerebral Amyloid Angiopathy"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients diagnosed with probable CAA using the Boston criteria; with no clinical\n             cognitive impairment\n\n          -  In general good health\n\n        Exclusion Criteria:\n\n          -  Co-morbid diagnosis of clinically documented Alzheimer's disease or significant\n             cognitive impairment\n\n          -  Clinically significant syncope, epilepsy, head trauma or clinically significant\n             unexplained loss of consciousness within the last 5 years\n\n          -  Subject's body weight exceeding 100kg\n\n          -  Women of childbearing potential."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "55 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01821118", 
            "org_study_id": "A9951024"
        }, 
        "intervention": [
            {
                "arm_group_label": "1", 
                "description": "Infusion of Ponezumab (Day 1=10mg/kg; Day 30 and Day 60 dose = 7.5mg/kg) or placebo (saline); administered via infusion for a total infusion time of 20 minutes.", 
                "intervention_name": "Ponezumab", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "2", 
                "description": "placebo (saline)- given via infusion total infusion time of 20 minutes", 
                "intervention_name": "placebo", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Cerebral amyloid angiopathy (CAA)", 
            "cerebrovascular reactivity", 
            "functional MRI", 
            "randomized", 
            "double blind", 
            "safety", 
            "efficacy"
        ], 
        "lastchanged_date": "May 21, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A9951024&StudyName=Study%20Evaluating%20the%20Safety%2CTolerability%20and%20Efficacy%20of%20PF-04360365%20in%20Adults%20with%20Probable%20Cerebral%20Amyloid%20Angiopathy%20"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90095"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02114"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02118"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charlestown", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02129"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10032"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Calgary", 
                        "country": "Canada", 
                        "state": "Alberta", 
                        "zip": "T2N 2T9"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M4N 3M5"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lille Cedex", 
                        "country": "France", 
                        "zip": "59037"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "WC1N 3BG"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada", 
                "France", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 2, Randomized, Double Blind Placebo Controlled Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of PF-04360365 (Ponezumab) in Adult Subjects With Probable Cerebral Amyloid Angiopathy", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change from baseline to Day 2 or day 90 in cerebrovascular reactivity as measured by the slope (amplitude over time to peak) from visual task-evoked fMRI.", 
            "measure": "Change from baseline to Day 2 or day 90 in cerebrovascular reactivity.", 
            "safety_issue": "No", 
            "time_frame": "screening +90 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01821118"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Change from baseline to Day 2 or Day 90 in cerebrovascular reactivity as measured by the time to peak, magnitude, and time to bseline from visual task-evoked fMRI.", 
                "measure": "Change from baseline to Day 2 or Day 90 in cerebrovascular reactivity.", 
                "safety_issue": "No", 
                "time_frame": "screening +90 days"
            }, 
            {
                "description": "Change from baseline of total plasma AB species at specified endpoints after the intial dose of study medication on the concentration", 
                "measure": "Change from baseline of total plasma AB species", 
                "safety_issue": "No", 
                "time_frame": "screening +240 days"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}